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Introduction: Dual inhibition of SRC- and EGFR-dependent
pathways may overcome acquired resistance to epidermal growth
factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for pa-
tients with lung adenocarcinoma with EGFR mutations. The SRC
inhibitor dasatinib demonstrates antitumor activity in gefitinib-
resistant cells lines and xenografts. Dasatinib is tolerable for
patients with advanced non-small cell lung cancer, and in com-
bination with erlotinib.
Methods: We conducted this phase II study of dasatinib 70 mg
twice daily in patients with EGFR-mutant lung adenocarcinoma and
acquired resistance to EGFR-TKIs. After a protocol amendment
based on evolving data about both drugs, patients received dasatinib
at a dose of 100 mg daily with continued erlotinib after developing
acquired resistance. Enrolled patients either harbored an activating
mutation in EGFR or experienced clinical benefit with single-agent
erlotinib or gefitinib, followed by RECIST documented progression
while being treated with an EGFR-TKI.
Results: Twenty-one patients were enrolled, 9 under the original
trial design and 12 after the protocol amendments. We observed no
complete or partial responses (0% observed rate, 95% confidence
interval: 0–18%). The median time to progression was 0.5 months
(range, 0.2–1.8 months) in patients treated with dasatinib and 0.9
months (range, 0.4–5 months) for patients treated with dasatinib and
erlotinib in combination. Pleural effusions and dyspnea were fre-
quent toxicities.
Conclusions: Dasatinib has no activity in patients with EGFR-
mutant lung adenocarcinoma with acquired resistance to erlotinib
and gefitinib.
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(J Thorac Oncol. 2011;6: 1128–1131)
Seventy percent of patients with lung adenocarcinomaharboring mutations in the epidermal growth factor recep-
tor (EGFR) gene experience a partial response when treated
with EGFR tyrosine kinase inhibitors (TKIs) erlotinib or
gefitinib.1 However, the majority of patients progress within
17 months of the start of the treatment.2 At least 50% of lung
cancer patients with acquired resistance to erlotinib or ge-
fitinib develop a secondary T790M mutation within EGFR,
and another 10 to 15% of patients demonstrate MET ampli-
fication.3–5 Therapies directed against these mechanisms of
acquired resistance are desperately needed.
SRC is a nonreceptor tyrosine kinase that demonstrates
increased protein levels in EGFR-dependent tumors. SRC and
EGFR are proteins capable of mutual phosphorylation that
share downstream effectors such as phosphatidylinositol
3-kinase/PTEN/Akt and STAT proteins.6 Because of these func-
tional associations, SRC kinase has been proposed as a target to
overcome acquired resistance in EGFR-mutant tumors.
Preclinical models demonstrate EGFR-mutant cell lines
containing either L858R (H3255) or exon 19 deletions (PC9
or HCC827) undergo apoptosis when treated with the SRC
inhibitor dasatinib.7 Gefitinib-resistant adenocarcinoma cells
with T790M (PC9/ZD) orMET amplification (HCC827 GR5)
undergo cell death when treated with dasatinib.8 Dasatinib
also inhibits tumor growth in HCC827 GR5 nude mouse
xenografts.8 Dasatinib has been studied in patients with
advanced solid tumors, with pleural effusions dose-limiting.9
Dasatinib can be combined with erlotinib in unselected pa-
tients with advanced non-small cell lung cancer (NSCLC).10
Given its preclinical rationale and early clinical trial
results, we conducted a phase II study of dasatinib in patients
with EGFR-mutant lung adenocarcinoma and acquired resis-
tance to the EGFR-TKIs erlotinib and gefitinib.
PATIENTS AND METHODS
Patients with lung adenocarcinoma meeting consensus
criteria for acquired resistance were eligible.11 All patients
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agreed to undergo a repeat tumor biopsy. This protocol was
reviewed and approved by the Institutional Review Board at
Memorial Sloan-Kettering Cancer Center.
Initial Study Design
Seven days after discontinuing erlotinib or gefitinib
therapy, patients began dasatinib at a dose of 70 mg twice
daily. Patients were evaluated by computed tomography scan
at 4 weeks, 8 weeks, and at 8-week intervals. Modified
Response Evaluation Criteria in Solid Tumors (version 1.1)
were used to assess response. Toxicities were graded using
the National Cancer Institute Common Terminology Criteria
of Adverse Events (version 3.0).
A Simon two-stage design was employed to calculate
an initial sample size of 12. Cohort expansion to 37 patients
was planned if one or more partial responses were observed.
If 4 or more of the first 12 patients developed grade 3 or 4
pleural effusions, the trial would be stopped.
Amended Design
Coincident with the start of this trial, we observed that
patients with acquired resistance who discontinued EGFR-
TKIs experienced symptomatic deterioration and accelerated
tumor growth with increased [18F]-fluorodeoxyglucose (FDG)
avidity on positron emission tomography scans.12 After restart-
ing erlotinib or gefitinib in these patients, tumors decreased in
size and SUVmax on repeat studies, and tumor-related symptoms
improved. Given these observations, we now recommend con-
tinued erlotinib in patients with acquired resistance while also
adding second-line treatment agents and amended this protocol
to allow patients to continue erlotinib in addition to beginning
dasatinib. In addition, new data indicated that dasatinib 100 mg
daily provided similar efficacy with less pleural effusions when
used to treat patients with chronic myelogenous leukemia
(CML),13 and we further amended this trial to allow a dose of
dasatinib 100 mg daily.
Mutational Analysis
Before initiating dasatinib, all patients underwent
tumor biopsies, preferably at a site of growing or new
disease. Genomic DNA was extracted from tumor speci-
mens, and all EGFR mutations (exon 19 deletions, L858R
and T790M substitutions) were identified by mutation-
specific polymerase chain reaction-based methods.14 Tu-
mor specimens were analyzed for MET amplification using
dual-color fluorescent in situ hybridization with a MET-
specific gene probe.5 MET amplification was defined as
having a MET:CEP7 ratio of 2:1.
RESULTS
Dasatinib 70 mg Twice Daily
Nine patients were enrolled under the original trial
design. The median age was 68 years, and 66% of patients
were women (Table 1). Similar numbers of patients in this
cohort harbored exon 19 deletions and L858R mutations in
their tumors. One patient had insufficient tissue for analysis
(Table 2).
Patients were treated for a median of 16 months with
primary EGFR-TKIs before developing acquired resistance
(Table 1). When rebiopsied at the time of study enrollment,
44% (4/9) of patients had developed T790M acquired resis-
tance mutations; none of the patients with adequate tissue for
fluorescent in situ hybridization testing exhibited MET am-
plification (0/4 tested) (Table 2).
There were no complete or partial responses observed
(0%, 95% confidence interval: 0–34%). All patients pro-
gressed within 2 months of starting dasatinib. The median
time until progression was 0.5 months (range, 0.2–1.8
months). The median overall survival was 13 months.
The combination of rapid disease progression among
these initial nine patients, the majority (6/9) of whom devel-
oped pleural effusions, prompted revisions to our protocol
design, although still 3 patients away from its required sam-
TABLE 1. Patient Characteristics
Characteristic
Dasatinib 70 mg
Twice Daily
(n  9)
Dasatinib 100 mg
Daily  Erlotinib
(n  12)
Age, median (range) 68 (35–80) 60 (51–73)
Female/male 6/3 7/5
Smoking history
Never 7 8
Former 1 3
Current 1 1
KPS (median) 80 80
Months (median) treated with
EGFR-TKI before developing
acquired resistance
16 (8–102) 21 (12–49)
KPS, Karnofsky performance score; EGFR-TKI, epidermal growth factor receptor
tyrosine kinase inhibitor.
TABLE 2. Molecular Studies of Tumor Specimens
Dasatinib 70 mg
Twice Daily
(n  9)
Dasatinib 100 mg
Daily  Erlotinib
(n  12)
Primary EGFR mutations
Exon 19 deletion 4 10
L858R 4 2
Unable to be testeda 1 0
Molecular abnormalities found
at the time of developing
acquired resistance
T790M  Exon 19 del 2 8
T790M  L858R 2 0
T790M not found  Exon
19 del
2 2
T790M not found  L858R 1 2
T790M unable to be testeda 2 0
MET amplification present 0 0
MET amplification absent 4 7
MET amplification unable to
be testeda
5 5
a Unable to be tested due to insufficient tumor tissue.
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ple size of 12. We decided the protocol revisions were
necessary (see Amended Design section) to effectively eval-
uate our original study hypothesis.
Dasatinib 100 mg Daily  Erlotinib
Twelve more patients were enrolled. The median age
was 60 years, and 58% were women (Table 1). The majority
(80%) of this cohort had tumors with exon 19 deletions
(Table 2). Patients received a median of 21 months of
primary EGFR-TKI therapy before the development of ac-
quired resistance (Table 1). At rebiopsy, 75% had T790M
(Table 2). MET amplification was not identified in the seven
specimens tested.
Twelve patients were treated with dasatinib and erlotinib,
and no complete or partial responses were observed (0% objec-
tive response rate, 95% confidence interval: 0–28%). Patients
were treated with dasatinib 100 mg daily and erlotinib for a
median of 0.9 months (range, 0.4–5.4 months).
Toxicities
The primary toxicity was the development and/or enlarge-
ment of preexisting pleural effusions and dyspnea. Among
patients treated with dasatinib alone, three patients required
hospitalization for thoracostomy tube placement. One patient
receiving dasatinib with erlotinib required a similar intervention.
Peripheral and facial edema was also reported.
Fatigue was another significant side effect, whether
patients were treated with dasatinib alone or with erlotinib.
Patients reported grade 3 fatigue in 2 of 9 (22%) and 2 of 12
(17%) of patients, respectively. Nausea and vomiting (one
episode of grade 3 toxicity each) as well as grade 2 diarrhea
were reported.
DISCUSSION
In this phase II trial of SRC inhibitor dasatinib, with and
without erlotinib, in patients with lung adenocarcinoma and
acquired resistance to erlotinib, no objective responses were
observed. Pleural effusions and dyspnea were the most fre-
quent and significant toxicities. Regardless of whether erlo-
tinib was continued, patients were treated with dasatinib for a
median of less than 1 month due to a combination of disease
progression and toxicity.
Haura et al.10 studied dasatinib and erlotinib in unse-
lected patients with advanced lung cancer previously un-
treated. Two partial responses were reported, one in a patient
whose tumor harbored an EGFR exon 19 deletion. This
response likely reflects solely the effect of erlotinib in a tumor
with a sensitizing EGFR mutation. Very recently, Johnson et
al. also reported the results of a phase II trial of single-agent
dasatinib as first-line treatment for unselected patients with
advanced NSCLC. Neither SRC activity nor mutations in
EGFR (or KRAS) were associated with the modest response
rates reported—overall disease control rate of 43% and
progression-free survival of 1.36 months.15
Pleural effusions were observed in 66% of patients
enrolled in this study. The pleural effusions observed were
clinically more significant for the patients who received
dasatinib 70 mg twice daily—50% of whom required thora-
centesis or tube thoracostomy. Only one patient treated with
dasatinib 100 mg daily and erlotinib required a tube thora-
costomy. Prior studies in patients with CML and advanced
solid tumors treated with dasatinib also observed pleural
effusions to be dose-related.9,13 Johnson et al.15 reported that
the presence of pleural effusions in patients with advanced
NSCLC before treatment with dasatinib predicted the devel-
opment of clinically significant effusions during treatment.
In many cases, it was difficult to discern whether these
new pleural effusions were dasatinib-related drug toxicity or
evidence of progressive cancer. Unlike patients with CML or
solid tumors other than lung cancer treated with dasatinib, in
whom pleural effusions can easily be recognized as drug
toxicity and managed with dose attenuation, diuretics, and
corticosteroids without treatment delays, this complication
proved very challenging to manage in our patients with lung
adenocarcinoma.
The amended trial design also limited interpretation of
the study’s negative results. We simultaneously changed the
dasatinib dosing schedule and added erlotinib to the treatment
regimen to incorporate the latest information about both
drugs. By making changes to two aspects of the trial design
at once, we clouded our ability to discern the true reason (or
reasons) for the disappointing results.
We found the combination of dasatinib and erlotinib to
be inactive, with significant toxicities. Our study suggests that
SRC inhibitors merit no further study in patients with EGFR-
driven lung adenocarcinoma. Therefore, these patients remain
ideal candidates for clinical trials investigating new strategies
to overcome acquired resistance.
ACKNOWLEDGMENTS
Supported by NCI grant CA 130343-01 and by an
American Society of Clinical Oncology Young Investigator
Award to Dr. Riely.
REFERENCES
1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-
paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–
957.
2. Janne PA, Wand XF, Socinski MA, et al. Randomized phase II trial of
erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in
never or light former smokers with advanced lung adenocarcinoma:
CALGB 30406. J Clin Oncol 2010;28(15s):Abstract 7503.
3. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung
adenocarcinomas to gefitinib or erlotinib is associated with a second
mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
4. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification
leads to gefitinib resistance in lung cancer by activating ERBB3 signal-
ing. Science 2007;316:1039–1043.
5. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or
without T790M mutations in EGFR mutant lung tumors with acquired
resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:
20932–20937.
6. Tice DA, Biscardi JS, Nickles AL, et al. Mechanism of biological
synergy between cellular Src and epidermal growth factor receptor. Proc
Natl Acad Sci USA 1999;96:1415–1420.
7. Song L, Morris M, Bagui T, et al. Dasatinib (BMS-354825) selectively
induces apoptosis in lung cancer cells dependent on epidermal growth
factor receptor signaling for survival. Cancer Res 2006;66:5542–5548.
8. Yoshida T, Okamoto I, Okamoto W, et al. Effects of Src inhibitors on
cell growth and epidermal growth factor receptor and MET signaling in
gefitinib-resistant non-small cell lung cancer cells with acquired MET
amplification. Cancer Sci 2010;101:167–172.
Johnson et al. Journal of Thoracic Oncology • Volume 6, Number 6, June 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1130
9. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and
drug-interaction study of dasatinib in patients with advanced solid
tumors. Cancer 2010;116:1582–1591.
10. Haura EB, Tanvetyanon T, Chiappori A, et al. Phase I/II study of the Src
inhibitor dasatinib in combination with erlotinib in advanced non-small-
cell lung cancer. J Clin Oncol 2010;28:1387–1394.
11. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired
resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357–
360.
12. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontin-
uation and reinitiation of erlotinib or gefitinib in patients with acquired
resistance to erlotinib or gefitinib followed by the addition of everoli-
mus. Clin Cancer Res 2007;13:5150–5155.
13. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition
with dasatinib 100 mg once daily preserves efficacy and improves
tolerability in imatinib-resistant and -intolerant chronic-phase chronic
myeloid leukemia. J Clin Oncol 2008;26:3204–3212.
14. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based
detection of epidermal growth factor receptor gene mutations in lung
adenocarcinomas. J Mol Diagn 2005;7:396–403.
15. Johnson FM, Bekele BN, Feng L, et al. Phase II study of dasatinib in
patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;
28:4609–4615.
Journal of Thoracic Oncology • Volume 6, Number 6, June 2011 Dasatinib for Patients with Acquired Resistance to Erlotinib
Copyright © 2011 by the International Association for the Study of Lung Cancer 1131
